HOME >> BIOLOGY >> NEWS
Interim analysis of anti-cancer vaccine, BiovaxID, to be conducted

Tampa, FL--June 13, 2007 -- Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announces a milestone in its effort to gain accelerated conditional approval for BiovaxID. The independent Data Monitoring Committee (DMC) has requested an interim analysis of all primary and secondary endpoints. The DMC is the independent committee that is responsible for safety and efficacy reviews of the BiovaxID Phase 3 Clinical Trial. Further, the DMC has requested data lock to occur in September 2007 to facilitate this interim analysis.

Additionally, the DMC has informed the Company that, after its review of unblinded data for the BiovaxID Phase 3 Clinical Trial, there are no identifiable safety concerns related to this therapy. The company believes that BiovaxIDs strong safety record will be supportive of its planned application for accelerated conditional approval of BiovaxID.

BiovaxID is an anti-cancer vaccine that is in pivotal Phase 3 Clinical Trial for the indication of non-Hodgkins lymphoma (NHL). BiovaxID is a personalized, patient specific vaccine designed to stimulate the patients own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating NHL, BiovaxID is designed to kill only cancerous B-cells. The BiovaxID Phase 3 clinical trial is being conducted at fourteen oncology centers within the United States and nineteen centers in Russia.

The Chairman of the DMC, Dr. Gerry Messerschmidt, MD, FACP, stated, There are no identifiable safety concerns in the current BiovaxID Phase 3 pivotal Clinical Trial at this time in our data review. To facilitate Biovests regulatory agency discussions and petitions based on its announced decision to seek accelerated conditional approval of BiovaxID, the DMC has requested that the database be fully updated and a
'"/>

Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
13-Jun-2007


Page: 1 2 3

Related biology news :

1. Interim Aranesp data suggest major response in anemic patients with MDS
2. Interim long-term follow-up data show AMG 531 increases platelets in patients with ITP
3. Interim data suggest major response with Aranesp(R) in anemic patients with MDS
4. AAAS analysis finds Congress would add billions to FY 2008 R&D investment
5. Genetic analysis finds greater threat in frog-killing fungus
6. Genomic analysis uncovers new targets for HIV vaccine
7. Manchester University helps with pharaoh DNA analysis
8. UN issues analysis of global investors sustainable energy gold rush
9. New NIST reference material for peptide analysis
10. New system for soil analysis
11. DNA analysis suggests under-reported kills of threatened whales

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... SOMERSET, N.J. (PRWEB) , ... July 01, 2020 ... ... today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility ... with the company’s existing Japanese clinical supply facility located in Kakegawa, the new ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... R&D, today announced that it has entered into a multi-year contract with ... to support their translational and clinical research strategy to discover and develop ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC , ... that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) ... with severe COVID-19. This is the first study of an XPO1 inhibitor in ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive four ... may choose which extremities they would like treated. , Several studies have shown just ... R3 International, umbilical cord tissue is obtained from a lab with a long history ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as the solution ... history of eSource, the reasons it did not take off as quickly as people ... the industry is moving towards capturing data electronically for clinical trials and then repurposing ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this new technology ... technology of its kind on the market and we were pleased that the IFT ... of traditional cultured ingredients, creating a natural way to extend the shelf life and ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... (PTU) is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical ... team led by Dr MA has been using the zebrafish model to investigate ...
Breaking Biology Technology:
Cached News: